Aylin Ulku, MD, PhD
At UCSF, her focus remains in social justice and health equity through a variety of efforts. She is a member of an anti-racist committee working to reduce bias in documentation in the UCSF Health electronic record. She works as an advocate for adults living with sickle cell disease, accompanying patients throughout their hospital stays when admitted for complications of sickle cell disease. She has worked for over a decade as a mentor in global health education as the Director of the Global Health Elective in the Internal Medicine Residency program as well as in the HEAL (Health, Equity, Action, Leadership) Initiative, a fellowship for health practitioners across with world working or health equity. Currently, she serves as the Associate Director of the HEAL Initiative Global Fellowship.
Aylin works full time as a clinician in both internal medicine and pediatric hospital medicine providing direct care or working with trainees as a coach and mentor.
Education:
- Princeton University, Chemistry (BA)
- University of North Carolina, Chapel Hill (MD-PhD - pharmacology)
- Yale-New Haven Hospital (internship, residency, chief resident)
Board Certifications:
- Internal Medicine (2010 to present)
- Pediatrics (2010 to present)
- Pediatric Hospital Medicine (2024)
Education
Honors and Awards
Campbell PM, Singh A, Williams FJ, Frantz K, Ulkü AS, Kelley GG, Der CJ. Genetic and pharmacologic dissection of Ras effector utilization in oncogenesis. Volume 407. Methods in enzymology 2006. PMID: 16757325
Pruitt K, Ulkü AS, Frantz K, Rojas RJ, Muniz-Medina VM, Rangnekar VM, Der CJ, Shields JM. Ras-mediated loss of the pro-apoptotic response protein Par-4 is mediated by DNA hypermethylation through Raf-independent and Raf-dependent signaling cascades in epithelial cells. Volume 280 of Issue 24. The Journal of biological chemistry 2005. PMID: 15831492
Collette J, Ulku AS, Der CJ, Jones A, Erickson AH. Enhanced cathepsin L expression is mediated by different Ras effector pathways in fibroblasts and epithelial cells. Volume 112 of Issue 2. International journal of cancer 2004. PMID: 15352030
Eckert LB, Repasky GA, Ulkü AS, McFall A, Zhou H, Sartor CI, Der CJ. Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis. Volume 64 of Issue 13. Cancer research 2004. PMID: 15231670
Ulkü AS, Schäfer R, Der CJ. Essential role of Raf in Ras transformation and deregulation of matrix metalloproteinase expression in ovarian epithelial cells. Volume 1 of Issue 14. Molecular cancer research : MCR 2003. PMID: 14707291
Vos MD, Ellis CA, Elam C, Ulku AS, Taylor BJ, Clark GJ. RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor. Volume 278 of Issue 30. The Journal of biological chemistry 2003. PMID: 12732644
Ulkü AS, Der CJ. Ras signaling, deregulation of gene expression and oncogenesis. Volume 115. Cancer treatment and research 2003. PMID: 12613198
Fiordalisi JJ, Johnson RL, Ulkü AS, Der CJ, Cox AD. Mammalian expression vectors for Ras family proteins: generation and use of expression constructs to analyze Ras family function. Volume 332. Methods in enzymology 2001. PMID: 11305105